Skip to main content

Hansoh Announces $122 Million Agreement to Acquire Rights to Antifungal

ansoh Pharma entered an $122 million agreement to acquire Greater China rights to a novel antifungal from Synexis of New Jersey . The agent, ibrexafungerp, is a first-in-class, broad-spectrum triterpenoid antifungal with both intravenous and oral formulations, aimed at overcoming drug resistant fungal infections. It is currently under review for US approval to treat vaginal yeast infections. Hansoh markets a broad portfolio of drugs, including anti-infectives, in China , the US and Asia . More details.... Stock Symbols: (HK: 3692) (NSDQ: SCYX) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.